Navigation Links
Misonix Exhibits BoneScalpel™ at the International Meeting on Advanced Spine Techniques
Date:10/25/2011

FARMINGDALE, N.Y., Oct. 25, 2011 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a medical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications, has announced their recent exhibition of the BoneScalpel™ Ultrasonic Bone Cutting System at the International Meeting on Advanced Spine Techniques which was held in Copenhagen, Denmark from July 13-16, 2011.  The meeting was hosted by the Scoliosis Research Society and was attended by approximately 800 physician opinion leaders from around the world who were exposed to the latest advancements in spinal deformity surgery.

The Scoliosis Research Society continues to maintain a commitment to research and education in the field of spinal deformities.  Current membership includes over 1,000 of the world's leading spine surgeons, researchers, physician assistants and orthotists who are involved in research and treatment of spinal deformities.

The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures.  It offers the convenience and speed of a power instrument while minimizing the peril associated with rotary sharps.

"We were excited about the opportunity to be part of this meeting of world leading experts in advanced spinal and spinal deformity surgery," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Our initial experience with orthopedic surgeons and neurosurgeons performing spinal deformity surgery has been very positive and the BoneScalpel has been received enthusiastically by some of the opinion leaders in the field.  Adoption of the BoneScalpel technology is advancing at an accelerating rate thanks to growing clinical experience in multiple surgical specialties and the expansion of our sales channel to global coverage."

About Misonix:

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment.  Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies.  Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships,  regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  The Company disclaims any obligation to update its forward-looking relationships.

Investor Relations Contact:  
Kevin McGrath/Cameron Associates, Inc.  
212-245-4577  
Kevin@cameronassoc.com


'/>"/>
SOURCE Misonix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern
2. Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results
3. Misonix, Inc. Announces the Sale of Sonora Medical Systems for $8 Million
4. Misonix Announces New Distribution Agreement for United Kingdom and Republic of Ireland
5. Misonix Announces New Distribution Agreement for Mexico
6. Misonix Schedules First Quarter 2010 Financial Results Conference Call; November 16, 2009 at 4:30 p.m. Eastern
7. Misonix Announces New Distribution Agreement for Saudi Arabia and Other Middle Eastern Countries
8. Misonix Announces New Distribution Agreement for Peru
9. Misonix Announces New Distribution Agreement For The United Arab Emirates (UAE)
10. Misonix Announces New Distribution Agreement for Argentina
11. Misonix Announces New Distribution Agreement for Kingdom of Saudi Arabia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... , May 27, 2016  A new study highlights the necessity of health literacy ... Journal of the American College of Radiology , a majority of oncology patients undergo ... Photo - http://photos.prnewswire.com/prnh/20160527/373022 ... ... Medical Diagnostic Imaging Ampronix ...
(Date:5/27/2016)... , May 27, 2016 LabStyle ... Dario™ Diabetes Management Tool, today announced that the Company,s Chief ... Marcum MicroCap Conference being held June 1-2 in ... being held June 7-9 in Los Angeles, CA. ... discuss recent corporate and operational milestones, including the U.S. FDA ...
(Date:5/27/2016)... According to the 2016 report, ... ambulatory blood pressure monitoring system market growth. With aging, ... to respond to different pressure rates, leading to hypertension ... various cardiovascular disorders such as heart failure, stroke, coronary ... growing in prevalence each year. WHO estimates that 17 ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... W.S. Badger Co. ... today that it has been recognized as one of the best small businesses for ... named as one of nine small businesses providing progressive benefits to new parents on ...
(Date:5/27/2016)... ... May 27, 2016 , ... In response to meager public ... unaware of the plight of aphasia. In collaboration with the American Aphasia Association, ... , The link between stroke and aphasia is relatively unknown, but through collaboration ...
(Date:5/27/2016)... ... May 27, 2016 , ... With a team of ... food industries. Aside from its GMP accreditation, Validation Center is also a registered ... products, services and staff. , Validation Center is ISO17025 accredited and only offers ...
(Date:5/26/2016)... ... 26, 2016 , ... Intalere, the healthcare industry leader in ... inaugural Member Conference at the Paris Hotel in Las Vegas, Nev., May 17-20, ... America’s healthcare providers. , The conference was highlighted by the announcement of the ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cardiac arrhythmia is a ... on long-term patient survival, reports a team of UPMC researchers in the largest ... the Journal of Thoracic and Cardiovascular Surgery, provide critical information that will hopefully ...
Breaking Medicine News(10 mins):